Contact information
benoit.vandeneynde@ludwig.ox.ac.uk
Benoit Van den Eynde's group page
Old Road Campus Research Building
Benoit Van den Eynde
Professor of Tumour Immunology
I am an expert in tumour immunology (MD, PhD) and I am currently a Member of the Ludwig Institute for Cancer Research and Director of the de Duve Institute, Belgium. I am also Full Professor of Immunology at the Université catholique de Louvain in Brussels and I train young scientists, including PhD students, medical students and postdoctoral Fellows from all over the world. I serve as member of several national and international scientific committees and editorial boards, and I am a full member of the Belgian Royal Academy of Medicine.
I initially identified, together with Thierry Boon, the first tumour rejection antigen naturally expressed by mouse tumours and recognised by CD8 T lymphocytes. I subsequently identified a number of human tumour antigens recognised by CD8 T lymphocytes and I studied their processing, i.e. how they are produced by the cell. This led to the discovery of peptide splicing by the proteasome and of novel proteasome subtypes. I also described how tumours resist immune rejection by degrading tryptophan, through the expression of indoleamine dioxygenase (IDO) or tryptophan dioxygenase (TDO).
I am co-founder of iTeos Therapeutics, a biotechnology company based in Gosselies (Belgium) launched in 2012 as a spin-off of Ludwig Cancer Research. Its activity consists in developing small molecule immunomodulators for cancer treatment. Its first compound, an IDO inhibitor, is at the stage of clinical testing in cancer patients.
In 2016, I started a second group at Ludwig Oxford, to develop synergies in the tumour immunology landscape, focusing on cancer vaccines. I am also Professor of Tumour Immunology at the University of Oxford.
I have published more than 175 scientific papers and books and given more than 150 invited lectures at international meetings. My work has been cited more than 15,000 times in the scientific literature.
Key publications
-
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Journal article
Uyttenhove C. et al, (2003), Nat Med, 9, 1269 - 1274
-
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Journal article
Dalet A. et al, (2011), Proc Natl Acad Sci U S A, 108, E323 - E331
-
An antigen produced by splicing of noncontiguous peptides in the reverse order.
Journal article
Warren EH. et al, (2006), Science, 313, 1444 - 1447
-
Production of an antigenic peptide by insulin-degrading enzyme.
Journal article
Parmentier N. et al, (2010), Nat Immunol, 11, 449 - 454
-
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Journal article
Pilotte L. et al, (2012), Proc Natl Acad Sci U S A, 109, 2497 - 2502
Recent publications
-
Novel H-2D<sup>b</sup>-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
Journal article
McAuliffe J. et al, (2024), Journal for immunotherapy of cancer, 12
-
Interferon-γ driven differentiation of monocytes into PD-L1+and MHC II+macrophages and the frequency of Tim-3+tumor-reactive CD8+T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice
Preprint
Gabrilo J. et al, (2024)